About US
Contact us
-
After FDA experts smack down ineffective decongestant, class-action lawsuits flyQuestions first circulated about decongestant pills containing phenylephrine in 2007. Sixteen years later, the products may be pulled from shelves nationwide as experts have concluded they don't work2023/9/22
-
FTC, amid biopharma M&A drive, says it will take action against 'sham' patentsAmid the Federal Trade Commission's (FTC's) campaign to bolster scrutiny aroundlarge biopharma M&A deals, the agency is now taking a closer look at patent gamesmanship. Thursday, the agency issue2023/9/19
-
Seeing green, AstraZeneca lays down £100M for 15-year renewable gas project in UKAstraZeneca, often at the forefront of biopharma's sustainability efforts, is making a big play to support renewable natural gas in its home country. Through a 100 million pound sterling ($124 millio2023/9/19
-
It's unanimous: FDA panel says decongestant drug phenylephrine does not workFor decades, hundreds of oral decongestant products containing phenylephrine have been available in the United States over the counter. But on Tuesday, an FDA advisory committee agreed by a 16-0 vote2023/9/14
-
Ferring begins bladder cancer gene therapy rollout through focused programAfter securing approval at the end of last year for a potential alternative to bladder removal in certain bladder cancer patients, FerringPharmaceuticalshas giventhe gene therapy Adstiladrinto its fi2023/9/14
-
HHS argues Merck 'lacks standing' to sue over Medicare price negotiationsMerck & Co. was the first drugmaker to sue over the controversial Medicare price negotiation provisions in last year’s Inflation Reduction Act (IRA). But the New Jersey drug giant “lacks standing2023/9/11
-
In warning letters, FDA tells 8 companies to stop selling illicit eye drugsEight companies are finding themselves inhot water for allegedly churning out illicit eye drugs, the FDA said Tuesday. The drugs are unapproved and illegally marketed, the FDA said, which is especial2023/9/11
-
Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analystsBiopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up2023/9/8
-
Amgen, J&J most vulnerable to IRA price negotiations in 2026: Moody'sNow that the Centers for Medicare & Medicaid Services (CMS) hasrevealedits list of the first 10 drugs subject to Medicare price negotiations under the Inflation Reduction Act (IRA), it’s time to2023/9/5
-
BlueWhale Bio surfaces with $18M on mission to overhaul cell therapy productionUniversity of Pennsylvania spinout BlueWhale Bio has surfaced on a mission to smash bottlenecks in cell and gene therapy manufacturing. The new companyuncloakedThursday with news it has raised $182023/9/5